David A. Bushinsky

Dr. David A. Bushinsky


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
DBDavid A. Bushinsky
David A. Bushinsky

1 July 2000 in Current Opinion in Nephrology and Hypertension
Verified
Journal Article
Closed access
DBDavid A. Bushinsky
David A. Bushinsky
KFKevin K. Frick
Kevin K. Frick
Metabolic acidosis induces calcium efflux from bone and in the process buffers the additional hydrogen ions. Initially metabolic acidosis stimulates physicochemical mineral dissolution and then cell-mediated bone resorption. Acidosis increases activity of the bone resorbing cells, the osteoclasts, and decreases activity of the bone forming cells, the osteoblasts. Osteoblastic immediate early response genes are inhibited as are genes controlling matrix formation.

1 December 2015 in Kidney International
Verified
Journal Article
Open access
PDF file
DBDavid A. Bushinsky
David A. Bushinsky
GWGordon H. Williams
Gordon H. Williams
BPBertram Pitt
Bertram Pitt
MWMatthew R. Weir
Matthew R. Weir
MFMason W. Freeman
Mason W. Freeman
GBGeorge L. Bakris
George L. Bakris
Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin–angiotensin–aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium in patients with CKD and hyperkalemia on RAASi. Here, patiromer’s onset of action was determined in patients with CKD and hyperkalemia taking at least one RAASi. After a 3-day potassium- and sodium-restricted diet in an inpatient research unit, those with sustained hyperkalemia (serum potassium 5.5 – under 6.5 mEq/l) received patiromer 8.4 g/dose with morning and evening meals for a total of four doses. Serum potassium was assessed at baseline (0 h), 4 h postdose, then every 2–4 h to 48 h, at 58 h, and during outpatient follow-up. Mean baseline serum potassium was 5.93 mEq/l and was significantly reduced by 7 h after the first dose and at all subsequent times through 48 h. Significantly, mean serum potassium under 5.5 mEq/l was achieved within 20 h. At 48 h (14 h after last dose), there was a significant mean reduction of 0.75 mEq/l. Serum potassium did not increase before the next dose or for 24 h after the last dose. Patiromer was well tolerated, without serious adverse events and no withdrawals. The most common gastrointestinal adverse event was mild constipation in two patients. No hypokalemia (serum potassium under 3.5 mEq/l) was observed. Thus, patiromer induced an early and sustained reduction in serum potassium and was well tolerated in patients with CKD and sustained hyperkalemia on RAASis.

1 January 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
DBDavid A. Bushinsky
David A. Bushinsky
Calcium (Ca) balance is the net of Ca intake and output from the body over a period of time. The concept of Ca balance does not consider the redistribution of Ca that often occurs in patients with chronic kidney disease (CKD), especially those who are on dialysis, which is often in the form of soft tissue and/or vascular calcification. In this article, we consider movement of Ca with respect to the extracellular fluid (ECF) and develop a mathematical formulation for Ca homeostasis with respect to the ECF that includes input and output from the diet, the bone, the kidney, and dialysis. We consider calcium homeostasis in healthy individuals and in patients with excess parathyroid hormone, excess 1,25-dihydroxyvitamin D3, and metabolic acidosis; patients who have CKD and are not on dialysis; and, finally, patients who have CKD and are on dialysis. On the basis of a number of assumptions, dialysis patients with a daily intake of >37.5 mmol of elemental Ca (1.5 g) have movement of Ca into the ECF even without supplemental activated vitamin D. Addition of activated vitamin D, which increases intestinal Ca absorption and can increase resorption of Ca from bone, leads to the movement of Ca into the ECF at virtually all levels of intake; however, there are numerous unanswered questions regarding Ca homeostasis in patients with CKD, including how much of the Ca, administered as a phosphate binder, is absorbed and what is the fate of this absorbed Ca. Until these pressing questions are answered with well-designed experiments, we do not know whether we are doing more harm than good for our dialysis patients by administering additional Ca as a phosphate binder, especially when they also receive activated vitamin D.

4 November 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
DBDavid A. Bushinsky
David A. Bushinsky
THThomas Hostetter
Thomas Hostetter
GKGerrit Klaerner
Gerrit Klaerner
YSYuri Stasiv
Yuri Stasiv
CLClaire Lockey
Claire Lockey
RARobert Alpern
Robert Alpern
Background and objectives: Metabolic acidosis is common in patients with CKD and has significant adverse effects on kidney, muscle, and bone. We tested the efficacy and safety of TRC101, a novel, sodium-free, nonabsorbed hydrochloric acid binder, to increase serum bicarbonate in patients with CKD and metabolic acidosis. Design, setting, participants, & measurements: One hundred thirty-five patients were enrolled in this randomized, double-blind, placebo-controlled, multicenter, in-unit study (designated the TRCA-101 Study). Patients had a mean baseline eGFR of 35 ml/min per 1.73 m 2 , a mean baseline serum bicarbonate of 17.7 mEq/L, and comorbidities, including hypertension (93%), diabetes (70%), and heart failure (21%). Patients ate a controlled diet and were treated for 14 days with placebo or one of four TRC101 dosing regimens (1.5, 3, or 4.5 g twice daily or 6 g once daily). After treatment, patients were discharged and followed for 7–14 days. Results: All TRC101 treatment groups had a mean within-group increase in serum bicarbonate of ≥1.3 mEq/L ( P <0.001) within 72 hours of the first dose and a mean increase in serum bicarbonate of 3.2–3.9 mEq/L ( P <0.001) at the end of treatment compared with placebo, in which serum bicarbonate did not change. In the combined TRC101 treatment group, serum bicarbonate was normalized (22–29 mEq/L) at the end of treatment in 35% of patients and increased by ≥4 mEq/L in 39% of patients. After discontinuation of TRC101, serum bicarbonate decreased nearly to baseline levels within 2 weeks. All adverse events were mild or moderate, with gastrointestinal events most common. All patients completed the study. Conclusions: TRC101 safely and significantly increased the level of serum bicarbonate in patients with metabolic acidosis and CKD.

1 December 2001 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
DBDavid A. Bushinsky
David A. Bushinsky
WPWalter R. Parker
Walter R. Parker
KAKristen M. Alexander
Kristen M. Alexander
NKNancy S. Krieger
Nancy S. Krieger
First published July 12, 2001; 10.1152/ajprenal.00355.2001.— A decrease in blood pH may be due to either a reduction in bicarbonate concentration ([HCO[ ]]; metabolic acidosis) or to an increase in Pco2(respiratory acidosis). In mammals, metabolic, but not respiratory, acidosis increases urine calcium excretion without altering intestinal calcium absorption, indicating that the additional urinary calcium is derived from bone. In cultured bone, chronic metabolic, but not respiratory, acidosis increases net calcium efflux ( JCa), decreases osteoblastic collagen synthesis, and increases osteoclastic bone resorption. Metabolic acidosis increases bone PGE2production, which is correlated with JCa, and inhibition of PGE2production inhibits this acid-induced JCa. Given the marked differences in the osseous response to metabolic and respiratory acidosis, we hypothesized that incubation of neonatal mouse calvariae in medium simulating respiratory acidosis would not increase medium PGE2levels, as observed during metabolic acidosis. To test this hypothesis, we determined medium PGE2levels and JCafrom calvariae incubated at pH ∼7.1 to model either metabolic (Met; [HCO[ ]] ∼11 mM) or respiratory (Resp; Pco2∼83 Torr) acidosis, or at pH ∼7.5 as a control (Ntl). We found that after 24–48 and 48–51 h in culture, periods when cell-mediated JCapredominates, medium PGE2levels and JCawere increased with Met, but not Resp, compared with Ntl, and there was a direct correlation between medium PGE2levels and JCa. Thus metabolic, but not respiratory, acidosis induces the release of bone PGE2, which mediates JCafrom bone.